---
created: '2026-02-13T19:04:41.107816Z'
description: This systematic review and meta-analysis of 46 randomized controlled
  trials (n=4,158 participants) evaluated the efficacy and safety of berberine for
  type 2 diabetes. Berberine significantly reduced fasting blood glucose, HbA1c, and
  improved lipid profiles through AMPK activation. The analysis demonstrated berberine's
  potential as an adjunct therapy for metabolic disorders.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/research/efficacy-and-safety-of-berberine-for-type-2-diabetes-a-systematic-review-and-meta-analysis/
slug: efficacy-and-safety-of-berberine-for-type-2-diabetes-a-systematic-review-and-meta-analysis
tags:
- research
- berberine
- AMPK
- type 2 diabetes
- meta-analysis
- glucose metabolism
- systematic review
templateEngineOverride: njk
title: 'Efficacy and safety of berberine for type 2 diabetes: A systematic review
  and meta-analysis'
type: research
updated: '2026-02-13T19:04:41.107816Z'
---

{% raw %}
<h1>Efficacy and safety of berberine for type 2 diabetes: A systematic review and meta-analysis</h1>
<h2>Study Information</h2>
<p><strong>Authors</strong>: Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J<strong>Journal</strong>: Frontiers in Pharmacology<br />
<strong>Publication Date</strong>: 2020-09-01<br />
<strong>Type</strong>: Meta-Analysis<br />
<strong>Study Design</strong>: Systematic Review and Meta-Analysis<strong>Citations</strong>: 285<strong>DOI</strong>: <a href="https://doi.org/10.3389/fphar.2020.01260">10.3389/fphar.2020.01260</a><strong>PMID</strong>: <a href="https://pubmed.ncbi.nlm.nih.gov/32891636/">32891636</a><strong>PMC</strong>: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453919/">PMC7453919</a><strong>Semantic Scholar</strong>: <a href="https://www.semanticscholar.org/paper/PMID:32891636">View</a></p>
<h2>Abstract</h2>
<p>This systematic review and meta-analysis of 46 randomized controlled trials (n=4,158 participants) evaluated the efficacy and safety of berberine for type 2 diabetes. Berberine significantly reduced fasting blood glucose, HbA1c, and improved lipid profiles through AMPK activation. The analysis demonstrated berberine's potential as an adjunct therapy for metabolic disorders.</p>
<h2>Keywords</h2>
<p>berberine, AMPK, type 2 diabetes, meta-analysis, glycemic control, lipid metabolism, insulin sensitivity</p>
<!-- NEO4J_CONTENT_START -->
<h2>Relationships</h2>
<p>No relationships found.</p>
<!-- NEO4J_CONTENT_END -->
<h2>Methodology</h2>
<pre><code class="language-yaml">'{&quot;databases_searched&quot;: [&quot;PubMed&quot;, &quot;Cochrane Library&quot;, &quot;EMBASE&quot;, &quot;CNKI&quot;, &quot;Wanfang&quot;],
  &quot;design&quot;: &quot;Systematic review and meta-analysis&quot;, &quot;inclusion_criteria&quot;: &quot;RCTs comparing
  berberine with placebo or standard care in T2DM&quot;, &quot;quality_assessment&quot;: &quot;Cochrane
  Risk of Bias tool&quot;, &quot;statistical_method&quot;: &quot;Random-effects model (DerSimonian-Laird)&quot;}'
</code></pre>
<h3>Study Design</h3>
<ul>
<li><strong>Sample Size</strong>: n=4158- <strong>Duration</strong>: 4-24 weeks (across included studies)#### Population Characteristics</li>
</ul>
<pre><code class="language-yaml">'{&quot;age_range&quot;: &quot;Adults with type 2 diabetes&quot;, &quot;health_status&quot;: &quot;Type 2 diabetes mellitus&quot;,
  &quot;participants&quot;: 4158, &quot;total_studies&quot;: 46}'
</code></pre>
<h2>Results</h2>
<h3>Key Findings</h3>
<pre><code class="language-yaml">'{&quot;primary&quot;: [{&quot;heterogeneity&quot;: &quot;I2 = 89%&quot;, &quot;name&quot;: &quot;Fasting blood glucose&quot;, &quot;p_value&quot;:
  &quot;&lt;0.00001&quot;, &quot;result&quot;: &quot;Significant reduction (MD: -0.87 mmol/L)&quot;}, {&quot;name&quot;: &quot;HbA1c&quot;,
  &quot;p_value&quot;: &quot;&lt;0.00001&quot;, &quot;result&quot;: &quot;Significant reduction (MD: -0.72%)&quot;}], &quot;secondary&quot;:
  [{&quot;name&quot;: &quot;Total cholesterol&quot;, &quot;result&quot;: &quot;Significant reduction (MD: -0.58 mmol/L)&quot;},
  {&quot;name&quot;: &quot;LDL cholesterol&quot;, &quot;result&quot;: &quot;Significant reduction (MD: -0.38 mmol/L)&quot;},
  {&quot;name&quot;: &quot;Triglycerides&quot;, &quot;result&quot;: &quot;Significant reduction (MD: -0.41 mmol/L)&quot;},
  {&quot;name&quot;: &quot;Adverse events&quot;, &quot;result&quot;: &quot;Mild GI symptoms, similar to control&quot;}]}'
</code></pre>
<h3>Statistical Analysis</h3>
<h4>Statistical Significance</h4>
<pre><code class="language-yaml">'{&quot;fbg&quot;: &quot;p &lt; 0.00001, MD: -0.87 mmol/L, 95% CI: -1.09 to -0.64&quot;, &quot;hba1c&quot;: &quot;p &lt; 0.00001,
  MD: -0.72%, 95% CI: -0.91 to -0.54&quot;}'
</code></pre>
<h4>Effect Sizes</h4>
<pre><code class="language-yaml">'{&quot;fbg_reduction&quot;: &quot;0.87 mmol/L (15.7 mg/dL)&quot;, &quot;hba1c_reduction&quot;: &quot;0.72%&quot;, &quot;nnt&quot;:
  &quot;Approximately 4-5 for clinically meaningful improvement&quot;}'
</code></pre>
<h2>Limitations</h2>
<ul>
<li>High heterogeneity among studies (I2 = 89%)</li>
<li>Variable berberine dosages (0.5-1.5 g/day)</li>
<li>Mostly Chinese study populations</li>
<li>Short to medium duration studies</li>
<li>Potential publication bias</li>
</ul>
<h2>Research Integrity</h2>
<h3>Funding Sources</h3>
<ul>
<li>National Natural Science Foundation of China</li>
<li>Shanghai Municipal Health Commission</li>
</ul>
<h3>Conflicts of Interest</h3>
<ul>
<li>None declared</li>
</ul>
<h2>Replication Status</h2>
<p>Consistent with previous meta-analyses; findings support earlier systematic reviews</p>
<h2>References</h2>
<ul>
<li>Yin J et al. Metabolism. 2008;57(5):712-717. PMID: 18442638</li>
<li>Kong W et al. Nat Med. 2004;10(12):1344-1351. PMID: 15531889</li>
<li>Zhang Y et al. J Clin Endocrinol Metab. 2008;93(7):2559-2565. PMID: 18397984</li>
</ul>
<h2>Source Data</h2>
<ul>
<li><strong>Source System:</strong> PubMed - <strong>Last Modified in Source:</strong> 2026-01-25T21:22:09.460007+00:00</li>
</ul>

{% endraw %}